Omalizumab

Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research[1][2]. The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.

Product Specifications

CAS Number

[242138-07-4]

Product Name Alternative

Olizumab; rhuMab-E25; IGE25; RG-3648

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/omalizumab.html

Purity

99.70

Solubility

H2O

Smiles

[Omalizumab]

Molecular Weight

(146.46 kDa)

References & Citations

[1]Peipei Liu, et al. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases. Front Immunol. 2020 Nov 27;11:596908.|[2]Seung Y Chu, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol. 2012 Apr;129 (4) :1102-15.|[3]Marcia A Chan, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013 Sep 2;3 (1) :29.